Correlation analysis on total lymphocyte count and CD4 count in HIV-infected patients: A retrospective evaluation

Abstract

CD4 count is the standard method for determining eligibility for highly active antiretroviral therapy (HAART) and monitoring HIV/AIDS disease progression, but it is not widely available in resource-limited settings. This study examined the correlation between total lymphocyte count (TLC) and CD4 count of HIV-infected patients before and after HAART, and assessed the thresholds of TLC for making decisions about the initiation and for monitoring HAART. A retrospective study was performed, and 665 HIV-infected patients with TLC and CD4 count from four counties (Shangcai, Queshan, Shenqiu and Weishi) were included in the study. Pearson correlation and receiver operating characteristic (ROC) were used. TLC and CD4 count after HAART was significantly increased as compared with pre-HAART (P<0.01). An overall positive correlation was noted between TLC and CD4 count (pre-HAART, r=0.73, P=0.0001; follow-up HAART, r=0.56, P=0.0001). The ROC curve between TLC and CD4 count showed that TLC ≤ 1200 cells/mm³ could predict CD4 < 200 cells/mm³ with a sensitivity of 71.12%, specificity of 66.35% at pre-HAART. After 12-month HAART, the optimum prediction for CD4 count < 200 cells/mm3 was a TLC ≤ 1300 cells/mm³, with a sensitivity of 63.27%, and a specificity of 74.84%. Further finding indicated that TLC change was positively correlated to CD4 change (r=0.77, P=0.0001) at the time point of 12-month treatment, and the best prediction point of TLC change for CD4 increasing was 135 cells/mm³. TLC and its change can be used as a surrogate marker for CD4 count and its change of HIV-infected individuals for making decisions about the initiation and for monitoring HAART in resource-limited settings.

Keywords

HIV/AIDS / CD4 count / total lymphocyte count / highly active antiretroviral therapy

References

[1] GautamH., SainiS., BhallaP., et al.. Use of total lymphocyte count to predict absolute CD4 count in HIV-seropositive cases. J Int Assoc Physicians AIDS Care (Chic Ill), 2010, 9(5): 292-295

[2] AragonèsG., Beltrán-DebónR., RullA., et al.. Human immunodeficiency virus-infection induces major changes in high-density lipoprotein particle size distribution and composition: the effect of antiretroviral treatment and disease severity. Clin Chem Lab Med, 2010, 48(8): 1147-1152

[3] ChaudharyM., KashyapB., GautamH., et al.. Use of surrogate markers to predict the HIV disease stage and time to initiate antiretroviral therapy in developing countries. J Int Assoc Physicians AIDS Care (Chic Ill), 2008, 7(5): 259-264

[4] MahajanA.P., HoganJ.W., SnyderB., et al.. Changes in total lymphocyte count as a surrogate for changes in CD4 count following initiation of HAART: implications for monitoring in resource-limited settings. J Acquir Immune Defic Syndr, 2004, 36(1): 567-575

[5] SrirangarajS., VenkateshaD.. Total lymphocyte count as a tool for timing opportunistic infection prophylaxis in resource-limited settings: a study from India. J Infect Dev Ctries, 2010, 4(10): 645-649

[6] KumarasamyN., MahajanA.P., FlaniganT.P., et al.. Total lymphocyte count (TLC) is a useful tool for the timing of opportunistic infection prophylaxis in India and other resource-constrained countries. J Acquir Immune Defic Syndr, 2002, 31(4): 378-383

[7] BakerC.A., ClarkR., VenturaF., et al.. Peripheral CD4 loss of regulatory T cells is associated with persistent viraemia in chronic HIV infection. Clin Exp Immunol, 2007, 147(3): 533-539

[8] FlorenceE., DreezenC., SchrootenW., et al.. The role of non-viral load surrogate markers in HIV-positive patient monitoring during antiviral treatment. Int J STD AIDS, 2004, 15(8): 538-542

[9] AnastosK., ShiQ., FrenchA.L., et al.. Total lymphocyte count, hemoglobin, and delayed-type hypersensitivity as predictor of death and AIDS illness in HIV-1 infected women receiving highly active antiretroviral therapy. J Acquir Immuno Defic Syndr, 2004, 35(4): 383-592

[10] LauB., GangeS.J., PhairJ.P., et al.. Rapid declines in total lymphocyte counts and hemoglobin concentration prior to AIDS among HIV-1-infected men. AIDS, 2003, 17(14): 2035-2044

[11] LiX., XuY., NieS., et al.. The effect evaluation of highly active antiretroviral therapy to patients with AIDS in Hubei province of China. J Huazhong Univ Sci Technol [Med Sci], 2009, 29(5): 580-584

[12] World Health Organization. Antiretroviral therapy for HIV infection in adults and adolescents: Recommendations for a public health approach. Available: www.who.int. Accessed 4 March 2010

[13] DakaD., LohaE.. Relationship between total lymphocyte count (TLC) and CD4 count among peoples living with HIV, Southern Ethiopia: a retrospective evaluation. AIDS Res Ther, 2008, 5: 26

[14] ChaissonR.E., KerulyJ.C., MooreR.D.. Association of initial CD4 cell count and viral load with response to highly active antiretroviral therapy. JAMA, 2000, 284(24): 3128-3129

[15] CheungC., ShuterJ.. Pneumocystis jirovecii prophylaxis discontinuation based upon total lymphocyte count in HIV-infected adults treated with antiretroviral therapy. Int J STD AIDS, 2010, 21(6): 406-409

[16] YeniP.G., HammerS.M., CarpenterC.C., et al.. Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA Panel. JAMA, 2002, 288(2): 222-235

[17] SabinC.A., LampeF.C., ChalonerC., et al.. An audit of antiretroviral treatment use in HIV-infected patients in a London clinic: the limitations of observational databases when auditing antiretroviral treatment use. HIV Med, 2003, 4(2): 87-93

[18] AkinolaN.O., OlasodeO., AdediranI.A., et al.. The search for a predictor of CD4 cell count continues: total lymphocyte count is not a substitute for CD4 cell count in the management of HIV-infected individuals in a resource-limited setting. Clin Infect Dis, 2004, 39(4): 579-581

[19] GuptaA., GupteN., BhosaleR., et al.. Low sensitivity of total lymphocyte count as a surrogate marker to identify antepartum and postpartum Indian women who require antiretroviral therapy. J Acquir Immune Defic Syndr, 2007, 46(3): 338-342

[20] MwamburiD.M., GhoshM., FauntleroyJ., et al.. Predicting CD4 count using total lymphocyte count: a sustainable tool for clinical decisions during HAART use. Am J Trop Med Hyg, 2005, 73(1): 58-62